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UKCCSG 9003 protocol
A Atra1, M Gerrard2, R Hobson3, JD lmeson3, S Ashley1 and CR Pinkerton1 on behalf of the UKCCSG
'Department of Paediatric Oncology, The Royal Marsden Hospital NHS Trust/Institute of Cancer Research, Downs Road, Sutton, Surrey SM2 5PT, UK;
2Sheffield Children's Hospital NHS Trust, Western Bank, Sheffield S10 2TH; 3UKCCSG, University of Leicester, Department of Epidemiology and Public Health,
22-28 Princess Road West, Leicester LE1 6TP, UK
Summary From June 1990 to February 1996, 35 patients with B-cell acute lymphoblastic leukaemia (B-ALL) 13 of whom had CNS disease
and 28 patients with stage IV B-cell non-Hodgkin's lymphoma (B-NHL) 22 of whom had CNS involvement were treated with a short, intensive
multiagent chemotherapy regimen (UKCCSG 9003 protocol) based on the French LMB 86 regimen. Fifty-five were boys. The age range was
11 months to 16.5 years (median 8.4 years). Chemotherapy included cyclophosphamide, vincristine, daunorubicin, high-dose methotrexate
(COPADM) and etoposide/high-dose cytarabine (CYVE) with frequent intrathecal (i.t.) triple therapy (methotrexate, cytarabine and
hydrocortisone). Cranial irradiation (24 Gy in 15 fractions) was recommended in patients with overt CNS disease. One patient with Wiskott-
Aldrich syndrome was withdrawn after entry and has been excluded from the analysis. Ten patients (16%) have relapsed (CNS, four; BM, two;
combined CNS and BM, three; and jaw, one) 4-11 months after diagnosis and two patients never achieved complete remission (CR). All have
died. In seven of the patients who relapsed, treatment had been modified or delayed because of poor clinical condition. Seven patients (11%)
died of toxicity 11 days to 4 months after diagnosis. The cause of death was sepsis (n = 5) or sepsis with renal failure (n = 2). With a median
follow-up of 3.1 years from diagnosis (range 9 months to 6.3 years), 43 patients (69%) survive in CR. This study confirms the effectiveness of
this regimen with regard to the relapse rate (16%), although the rate of toxic death is of concern.
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The treatment ofB-NHL in children is one ofthe success stories in
paediatric oncology. The cure rate has increased from less than
20% before 1980 (Al-Attar et al, 1979) to over 70% in the 1980s
and 1990s (Philip et al, 1982; Al-Attar et al, 1986; Patte et al,
1990). Recent studies have concentrated on improving outcome in
the remaining poor-risk subgroups (Hann et al, 1988; Patte et al,
1991; Cairo et al, 1996), reducing early deaths by aggressive treat-
ment of early renal and infectious complications (Lynch et al,
1977; Allegretta et al, 1985) and avoiding debulking surgery
(Frappaz et al, 1988; Al-Attar et al, 1989).
In 1986, the French paediatric oncology group (SFOP) intro-
duced a regimen for poor-risk patients with increased intensity of
early intrathecal (i.t.) therapy and the use of high-dose cytarabine
(LMB 86). Before this, results in patients with CNS disease were
disappointing, despite the use of craniospinal irradiation with
chemotherapy regimen, which was very effective in less advanced
disease (Philip et al, 1982; Chilcote et al, 1991). The subsequent
results with LMB 86 were dramatic, with a survival rate over 70%
(Rubie et al, 1988). Relapse of the underlying disease remains a
major cause of treatment failure. The use of high-dose cytarabine
and etoposide (CYVE) may help in relapsed or refractory cases
(Gentet et al, 1990).
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In this national study of unselected patients, a short, intensive
multiagent chemotherapy protocol (UKCCSG 9003) based on the
French LMB 86 regimen was used in an attempt to replicate the
French results.
PATIENTS AND METHODS
Between June 1990 and February 1996, 63 consecutively diagnosed
and previously untreated patients were entered into the study.
Informed consent was obtained from all patients and theirparents, as
appropriate. Fifty-five patients were male. Ages ranged from 11
months to 16.5 years (median 8.4 years). For the purpose of this
study, an adaptation ofthe SFOP definition ofhigh-risk patients was
used. B-ALL was defined as the presence ofmore than 25% L3-type
blasts in the bone marrow with symptoms of bone marrow involve-
ment, i.e. bone pain and/or myelosuppression, or more than 70% L3-
type blasts in the bone marrow. Thirty-five patients were considered
to have B-ALL, of whom 13 had CNS disease at presentation.
Twenty-eight patients had stage IV B-NHL, defined by the presence
ofnodal disease and up to 70% L3 blasts in the bone marrow, and 22
of these had CNS disease at presentation. The latter was defined as
the presence of more than 5 ,ul-' blasts in the cerebrospinal fluid
(CSF), cranial nerve palsy or tumour with intracranial extension. If
classified by the standard Murphy system, 44patients had B-ALL i.e.
>25% bone marrow involvement, ofwhom 16 had CNS disease, and
19 had stage IV B-NHL with <25% L3 blasts in the bone marrow, all
ofwhom had CNS disease.
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Figure 1 Schema of the UKCCSG 9003 protocol. *High dose; #low dose
The diagnosis ofB-NHL was defined cytologically and immuno-
logically in all cases using bone marrow aspirates, CSF, pleural or
ascitic fluid. A biopsy ofa lymph node orothertissues was obtained
if other tests were negative. All pathology specimens and biopsies
were reviewed centrally. Staging investigations included bilateral
bone marrow aspirates, CSF cell count and cytospin, chest radiog-
raphy and ultrasonography with or without computerized tomo-
graphic (CT) scan of the primary tumour. Aggressive surgical
attempts to resect primary or bulky nodal disease were discouraged.
The aim of surgical procedure was to solely obtain adequate biopsy
material for histopathological diagnosis.
Initial induction chemotherapy consisting of low-dose
cyclophosphamide, vincristine and prednisolone (COP) was
designed to achieve cytoreduction with minimal toxicity. This
could be repeated once if the patient's clinical condition was very
poor. This treatment was followed by an intensive multiagent
chemotherapy regimen comprising cyclophosphamide, vincristine,
doxorubicin, high-dose methotrexate (COPADM) and etoposide/
high-dose cytarabine (CYVE) with frequent i.t. triple therapy
(methotrexate, cytarabine and hydrocortisone) (Figure 1 and Table
1). It was recommended that patients with CNS disease atdiagnosis
received cranial irradiation using 24 Gy in 15 fractions given after
COPADM3, i.e. week 15. Thirty-five patients had CNS disease at
presentation but, as a result ofdecisions by individual investigators,
only 11 received cranial radiotherapy. In addition, one patient was
given craniospinal irradiation and a further patient with testicular
involvement at diagnosis was also given testicular irradiation
24 Gy in addition to cranial irradiation.
Supportive care during induction included hyperhydration with
intravenous dextrose saline 31 m-2 per day and allopurinol 10 mg
kg-' per day. Dialysis (peritoneal orhaemodialysis) was performed
according to the clinical situation. Broad-spectrum antibiotics,
blood and platelet transfusions and total parental nutrition (TPN)
were used as indicated. Prophylactic use of granulocyte colony-
stimulating factor (G-CSF) was not recommended.
Response to chemotherapy was monitored by appropriate
restaging investigations after COP and CYVE2. At the end of
treatment, patients were assessed to confirm continued complete
remission (CR) using clinical criteria, bone marrow samples,
radiological investigations and exclusion of evidence of CNS
disease. Follow-up after finishing treatment was by 1- to 2-
monthly clinical review and other supplementary tests ifclinically
indicated during the first year and less often subsequently. Late
sequelae were documented on annual follow-up forms sent to each
centre.
Table 1 UKCCSG 9003 protocol
Regimen Dose Administration
COP
Cyclophosphamide 300 mg m-2 i.v. bolus day 1
Vincristine 1 mg m-2 i.v. bolus day 1
Prednisolone 60 mg m-2 day-' oral days 1-7
Triple i.t. therapy day 1,3,5
COPADM 1
Vincristine 2 mg m-2 i.v. bolus day 1
Doxorubicin 60 mg m-2 i.v. over 6 h day 2
Cyclophosphamide 500 mg m-2 day-' i.v. bolus 12 h + mesna days 2-4
High-dose MTX 8gm-2 i.v. over 3 h day 1
Folinic acid rescue 15 mgm-2 i.v. from day 2
Triple i.t. therapy day 1,3,5
Prednisolone 60 mg m-2 day-' oral days 1-5
COPADM 2 as COPADM 1 except
Vincristine 2 mg m-2 i.v. bolus day 1,6
Cyclophosphamide and mesna doses doubled i.e. 1 g m-2 day-'
CYVE (high-dose)
Cytarabine 50 mg m-2 i.v. over 12 h days 1-5
Cytarabine 3gm-2 i.v. over 3 h days 1-4
Etoposide 200 mg m-2 i.v. over2h days 1-4
Predsol eye drops for 4 days
COPADM 3 as COPADM 1 except
Cyclophosphamide 500 mg m-2 day-1 i.v. bolus 12-hourly with no mesna days 2+3
Triple i.t. therapy day 1
CYVE (low-dose)
Cytarabine 100 mg m-2 day-' i.v. or s.c. in two injections days 1-5
Etoposide 150 mg m-2 day-' days 2-4
COPAD
As COPADM 3, but without high-dose MTX
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Table 2 Details of relapsed cases
Diagnosis Site of relapse Time of relapse Time of death
from diagnosis after relapse
B-NHUCNS-a BM+CNS 6 months 23 days
B-ALUCNS- BM 10 months 1 month
B-NHUCNS+b CNS 6 months 3 months
B-ALUCNS- CNS 5 months treated with BMT,
but relapsed in BM and died
3 months later
B-ALUCNS- CNS 8 months 1 months
B-ALUCNS- Jaw 7 months 4 months
B-NHUCNS+ BM/CNS 4 months 1 week
B-NHUCNS+ CNS 5 months 2 months
B-ALUCNS+ BM 6 months 2 weeks
B-ALUCNS- BM+CNS 5 months 2 months
aCNS negative; bCNS positive.
Table 3 Details of toxic deaths
Diagnosis Cause Time from diagnosis
B-ALUCNS-a Septicaemia after CYVE II 4 months
B-NHL-CNS+b Septicaemia + renal failure after 1 month
COPADM
B-NHL-CNS+ Candida peritonitis + renal failure 11 days
and small intestinal perforation
B-ALUCNS- Disseminated aspergillosis after 4 weeks
third COP
B-ALUCNS- Fungaemia + GI bleeding after 6 weeks
COPADM 1
B-ALUCNS- S. aureus septicaemia and 3 weeks
peritonitis after COPADM 1
B-NHL-CNS+ Pneumonia + hypertension 5 weeks
after COPADM 1
aCNS negative; bCNS positive
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Figure 2 Overall survival of all patients.
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RESULTS/OUTCOME
One patient with stage IV B-NHL and CNS disease at presentation
was subsequently diagnosed as having Wiskott-Aldrich syndrome
and was withdrawn from the study after receiving the first two
blocks of treatment. Two patients with B-ALL and CNS disease at
presentation never achieved CR and died 4 and 11 months after
diagnosis. Ten patients (16%) relapsed after achieving CR 4-11
months after diagnosis (median 6.4 months). Sites of relapse were
CNS (n = 4), bone marrow (n = 2), combined CNS and bone
marrow (n = 3) and jaw (n = 1). In six of these patients, the early
treatment (block 2 and/or 3) had to be delayed or modified, and in
another patient the later blocks had to be delayed because of poor
clinical condition or other associated complications, mainly infec-
tious or metabolic. Similar delays occurred in 21 patients who did
not relapse and in four patients who died of toxicity. Eight of the
patients who relapsed received palliative chemotherapy. Two were
treated with high-dose cyclophosphamide and total-body irradia-
tion (TBI) followed by allogeneic bone marrow transplantation
(BMT). Both relapsed in the bone marrow 3 and 24 months after
BMT. All have died.
One patient with CNS disease at presentation received cranio-
spinal irradiation relapsed in the CNS and died 2 months later,
whereas the remaining 12 patients remain in CR. Twenty-two
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Figure 3 Event-free survival of all patients
patients with CNS disease at diagnosis did not receive irradiation.
Seventeen are alive in CR and five relapsed and died (Table 2).
Toxicity
Seven patients (11I%) died of toxicity between 11 days and 4
months (median 1.3 months) after diagnosis. The cause of death
was sepsis, bacterial or fungal (n = 5), or sepsis combined with
renal failure (n = 2) (Table 3). Five ofthese patients presented with
renal failure at diagnosis or after the initiation ofinduction therapy
and all required dialysis (peritoneal or haemodialysis). Among the
43 survivors, five patients required dialysis for renal failure at
presentation or shortly after the initiation ofchemotherapy.
Survival
With a median follow-up of 3.1 years from diagnosis (range 9
months to 6.3 years), 43 patients (69%) survive in complete remis-
sion (CI 55-79%) (Figure 2) with event-free survival (EFS) of
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Figure 4 Overall survival of patients with B-ALL vs stage IV B-NHL
69% (CI 57-79%) (Figure 3). Twenty-three patients (64%) (CI
46-78Yo) with B-ALL and 20 patients (74%) (CI 55-87%) with
stage IV B-NHL survive (Figure 4), with EFS 66% (CI 49-79%)
and 74% (CI 55-87%) respectively (Figure 5). Fifteen patients out
of 24 with B-ALL and no CNS disease at diagnosis are relapse
free, EFS 63% (CI 43-79%). Eight out of 11 patients with B-ALL
and CNS involvement are relapse free and well, EFS 73% (CI
43-90%). Two of the long-term survivors developed mild
cardiomyopathy requiring continuous captopril but remain
symptom free. Two patients have features of upper motor neurone
lesion in the lower limbs secondary to spinal cord compression at
presentation. One patient had delayed puberty and required testos-
terone (Sustanon) therapy and another patient continued to have
mild thrombocytopenia requiring no therapy. Another patient was
diagnosed as having osteochondritis of the L 1-L5 vertebrae
causing backache and requiring regular analgesia. Another
survivor was subsequently found to be HIV positive 4 years after
the initial diagnosis of lymphoma.
DISCUSSION
The use of a short, intensive multiagent regimen (UKCCSG
MACHO protocol) resulted in improved prognosis for B-ALL
patients and those with stage IV disease (Hann et al, 1988). The
LMB 86 protocol improved the disease-free survival further by
increasing the dose of high-dose methotrexate and cytarabine and
the frequency of intrathecal medications (Rubie et al, 1988). The
significance of partial substitution of ifosfamide for cyclophos-
phamide in the German study is difficult to interpret, but has not
significantly improved the results of treatment (Reiter et al, 1989,
1995).
The role of radiotherapy to achieve local control in patients with
CNS disease at presentation remains controversial. Avoidance of
cranial irradiation would help to reduce long-term endocrine and
neurological sequelae and is therefore desirable. The omission of
cranial irradiation from the treatment of patients with advanced
B-NHL and B-ALL without CNS disease at presentation did not
affect the event-free survival or the risk ofCNS relapse (Patte et al,
1986). In the LMB 89, the use ofhigh-dose systemic chemotherapy
Year from diagnosis
Figure 5 Event-free survival of all patients with B-ALL vs stage IV B-NHL
resulted in event-free survival of 87% in patients with B-ALL
without CNS involvement and 81% in those with CNS disease at
presentation (Patte et al, 1996). Only those with CNS disease
received cranial irradiation. Bowman et al (1996) reported their
results of 133 patients, 74 with B-ALL and 59 with stage IV B-
NHL, using intensive short-course chemotherapy regimen with
intrathecal MTX and Ara-C. The 4-year EFS was 65% and 79% for
B-ALL and stage IV B-NHL respectively. For those with CNS
involvement, the 4-year EFS was 64% without using radiotherapy.
It is of interest that in the present study CNS irradiation was selec-
tively omitted in many patients without any apparent adverse effect
on outcome.
Reduction in the total duration of therapy from 7 months to 4
months in the LMB 84 study did not lead to a difference in event-
free survival and overall survival between both arms (Patte et al,
1991), but the toxic death rate was reduced from 10% to 6% in the
4-month therapy arm. It was concluded from this and another
study (Schwenn et al, 1991) that long term CR can be achieved
without reducing the overall survival rate by reducing the overall
duration of treatment. It seems likely that a shorter regimen
than 9003 could be equally effective. How high the dose of indi-
vidual chemotherapy agents, e.g. cyclophosphamide, need to be is
debatable.
In 1991 the Children's Cancer Study Group (CCSG) compared
the results of treatment of children with high-risk B-NHL with
bone marrow or CNS involvement in a randomized study using the
LMB-89 and CCSG hybrid labelled 'orange'. The 2-year event-
free survival was not significantly different - 80% with the LMB
regimen and 84% with the CCSG regimen, but with more signifi-
cant toxicity and longer hospitalization with the former (Cairo et
al, 1996). The Paediatric Oncology Group (POG) 86 study used
fractionated cyclophosphamide with doxorubicin and vincristine
followed by MTX 1 g m-2 and high-dose Ara-C. Eighty-one
patients with B-ALL and stage IV B-NHL were treated with an
event-free survival of 61 % and 7 1 % respectively. In patients with
CNS disease at presentation (n = 24), the event-free survival was
52% without using irradiation (Brecher et al, 1992). To compare
with published studies and ifthe Murphy staging system is used in
the present study, all patients except two who had extensive
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100 -
90
80 -
70 -
60 -
50 -
40 -
30 -
20 -
10 -
Cl)
|, IV
ALL
5 6
---
.1 ij
I uI
0 Cancer Research Campaign 1998Cure rates in children with B-ALL and B-NHL 2285
paraspinal disease would be defined as B-ALL with CNS disease.
Their overall EFS is 69%.
With the 9003 regimen, despite the encouraging overall
survival, early toxic death and relapse remain important causes of
treatment failure. Many of these patients are extremely ill and
malnourished at presentation. Toxic death shortly after diagnosis
or after initial treatment is an important cause of treatment failure.
Early metabolic complications (hyperuricaemia and renal failure)
may precede therapy and contribute not only to early toxic death
but also to subsequent intolerance ofchemotherapy. Despite initia-
tion of hyperhydration and allopurinol, toxic deaths continue
to occur. The introduction of urate oxidase (uricozyme), which
converts uric acid to the stable allantoic acid, may help to reduce
the risk of metabolic complications (Masera et al, 1982).
Early response to induction treatment is an important prognostic
factor (Patte et al, 1986; Patte et al, 1991), and delay in initiating
treatment or modification of early treatment because of poor
general condition may contribute to subsequent treatment failure.
In this study, there was, however, no evidence that this contributed
to subsequent relapse. Long-term endocrine problems were
uncommon. Two patients developed mild cardiomyopathy
requiring regular medication. Both are well and their cardiac
dysfunction does not interfere with their daily activities.
An international study started in April 1996 is being conducted
by SFOP, CCCG and UKCCSG. Children with advanced B-
NHL/leukaemia are randomized to receive treatment of differing
intensity. The primary aim ofthe study is to confirm that the event-
free survival is not substantially altered by reducing the intensity
and the duration of treatment. Children with CNS involvement
will receive high-dose systemic chemotherapy and regular
intrathecal medications but no cranial irradiation. The hope is to
reduce the long-term toxicity, particularly cardiotoxicity, impaired
fertility and secondary malignancy, without jeopardizing the
overall success rate.
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